Adaptive Biotechnologies (ADPT) CCO Susan Bobulsky Sells 1,299 Shares

What Happened
Susan Bobulsky, Chief Commercial Officer of Adaptive Biotechnologies (ADPT), sold 1,299 shares of company stock on July 30, 2026. The shares were disposed at $24.00 per share for a total transaction value of $31,176. This was a sale (not a purchase or option exercise) reported on a Form 4.

Key Details

• Transaction date: July 30, 2026 — sale of 1,299 shares at $24.00 each (total $31,176).
• Transaction type: Sale (open market or private sale), reported on Form 4 filed August 3, 2026.
• Shares owned after transaction: Not disclosed in the provided filing excerpt.
• Footnote: The sale was made pursuant to a pre-established Rule 10b5-1 trading plan adopted by Ms. Bobulsky on December 16, 2025.
• Filing timeliness: Form 4 was filed August 3, 2026 for a July 30 transaction (appears to be within the standard two-business-day reporting window).

Context
A sale under a 10b5-1 plan is typically a prearranged, scheduled trade and is often considered routine rather than a direct signal of the insider’s view on the company. The transaction value here ($31K) is modest relative to typical executive trades; no options exercise, gift, or tax-withholding event is indicated in the provided details.